导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.40% | 2307/4773 |
| 近一周 | -1.94% | 3160/5465 |
| 近一月 | -6.14% | 4056/5421 |
| 近一季 | -13.65% | 4179/5231 |
| 近半年 | -5.00% | 2975/4920 |
| 近一年 | 4.02% | 1947/4394 |
| 近两年 | 72.11% | 978/2954 |
| 近三年 | 37.26% | 835/2253 |
| 成立以来 | 27.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.48% 1816/4961 |
20.97% 1195/5312 |
- - |
- - |
| 2025 | 31.42% 1239/4813 |
0.83% 1760/3635 |
0.48% 2634/4076 |
29.64% 1213/4524 |
0.05% 2253/4813 |
| 2024 | 10.94% 1357/3463 |
-1.46% 1228/2808 |
-4.84% 1571/3014 |
19.61% 825/3129 |
-1.08% 1581/3463 |
| 2023 | -12.83% 1510/2656 |
6.36% 696/2280 |
-5.25% 1409/2385 |
-8.07% 1659/2515 |
-5.91% 1551/2655 |
| 2022 | -25.29% 1307/2207 |
-18.51% 1349/1919 |
7.12% 526/2016 |
-16.18% 1412/2113 |
2.10% 1040/2208 |
| 2021 | 5.36% 547/1822 |
-4.57% 876/1255 |
11.32% 381/1330 |
-4.60% 723/1466 |
3.95% 380/1822 |
| 2020 | 42.42% 270/1250 |
-4.58% 377/1028 |
21.19% 243/1067 |
9.45% 648/1164 |
12.52% 459/1184 |
| 2019 | 45.78% 144/1092 |
36.84% 80/754 |
-6.64% 516/804 |
3.36% 256/850 |
10.40% 139/918 |
| 2018 | -34.07% 564/834 |
- - |
- - |
- - |
-13.79% 554/691 |
| 2017 | 10.38% 300/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.70% 425/605 |
- - |
- - |
- - |
- - |
| 2015 | 15.36% 140/575 |
- - |
- - |
- - |
- - |
| 2014 | 36.99% 139/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.32% 145/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.77% 92/140 |
- - |
- - |
- - |
- - |
| 2011 | -28.27% 85/102 |
- - |
- - |
- - |
- - |
| 2010 | -7.15% 18/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 南方深证成份ETF VS. 长安沪深300非周期A(740101) |